Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Shares Outstanding (Weighted Average): 2012-2025

Historic Shares Outstanding (Weighted Average) for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Sep 2025 value amounting to $21.4 million.

  • Enanta Pharmaceuticals' Shares Outstanding (Weighted Average) rose 0.89% to $21.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year increase of 0.89%. This contributed to the annual value of $21.4 million for FY2025, which is 0.89% up from last year.
  • Enanta Pharmaceuticals' Shares Outstanding (Weighted Average) amounted to $21.4 million in Q3 2025, which was up 0.01% from $21.4 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $21.4 million during Q3 2025, with a 5-year trough of $20.2 million in Q1 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $21.2 million (2024), whereas its average is $21.2 million.
  • Data for Enanta Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY grew of 2.56% (in 2022) over the last 5 years.
  • Enanta Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarterly) stood at $20.3 million in 2021, then climbed by 2.33% to $20.8 million in 2022, then increased by 1.26% to $21.1 million in 2023, then climbed by 0.64% to $21.2 million in 2024, then grew by 0.89% to $21.4 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $21.4 million in Q3 2025, compared to $21.4 million in Q2 2025 and $21.3 million in Q1 2025.